Kbc Group Nv Zai Lab LTD Transaction History

Kbc Group Nv

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$22.97 - $30.58 $605,098 - $805,568	-26,343 Reduced 87.48%	3,770 $103,000
Q3 2023 Feb 15, 2024	SELL	$22.72 - $31.49 $598,512 - $829,541	-26,343 Reduced 87.48%	3,770 $92,000
Q2 2023 Feb 15, 2024	BUY	$25.3 - $39.67 $429,897 - $674,072	16,992 Added 129.5%	30,113 $835,000
Q2 2023 Jul 28, 2023	BUY	$25.3 - $39.67 $429,897 - $674,072	16,992 Added 129.5%	30,113 $0
Q3 2022 Feb 15, 2024	BUY	$34.2 - $51.69 $319,804 - $483,353	9,351 Added 248.04%	13,121 $449,000
Q4 2021 Feb 14, 2024	BUY	$54.9 - $105.21 $513,369 - $983,818	9,351 Added 248.04%	13,121 $825,000
Q4 2021 Feb 03, 2022	BUY	$54.9 - $105.21 $182,707 - $350,138	3,328 Added 33.98%	13,121 $825,000
Q2 2021 Aug 11, 2021	BUY	$125.11 - $180.0 $124,109 - $178,560	992 Added 11.27%	9,793 $1.73 Million
Q1 2021 Apr 26, 2021	SELL	$126.27 - $191.71 $193,445 - $293,699	-1,532 Reduced 14.83%	8,801 $1.17 Million
Q4 2020 Feb 10, 2021	BUY	$81.94 - $135.34 $444,114 - $733,542	5,420 Added 110.32%	10,333 $1.4 Million
Q2 2020 Aug 10, 2020	BUY	$48.82 - $82.53 $239,852 - $405,469	4,913 New	4,913 $404,000

116

40.8M

63.1K

420K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.02B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

Stay updated on Kbc Group Nv with notifications on news.